Resources

"Amyloidosis Research Consortium Cardiac Amyloidosis Survey: An International Analysis of the Diagnostic Journey in AL and ATTR Amyloidosis," was presented at the 23rd annual Heart Failure Society of America meeting from September 13-16, 2019 in Philadelphia, PA. This poster presents results from 745 patients and caregivers and highlights regional differences, changes over time, and how we can improve the diagnostic journey of amyloidosis patients.

ARC-supported consensus best practices guidelines for the diagnosis of cardiac ATTR amyloidosis published in the journal of the American Heart Association, Circulation: Heart Failure.

These practice points from the American Society of Nuclear Cardiology (ASNC) are to identify the critical components involved in performing (99m) Tc-PYP imaging for the evaluation of cardiac transthyretin amyloidosis (ATTR).

Presented in February 2019 by: Sharmila Dorbala, MD, MPH, FASNC; Ronald M. Witteles, MD; Mazen Hanna, MD; and Martha Grogan, MD,

Presented in March 2019 by: Sharmila Dorbala, MD, MPH, FASNC; Jamieson Bourque, MD; Frederick Ruberg, MD; and Wael Jaber, MD.

Presented in May 2019 by: Sharmila Dorbala, MD, MPH, FASNC; Prem Soman, MD, MASNC; Rodney Falk, MD; and Mathew Maurer, MD.

ARC's comprehensive research strategy promotes a "from the patient's bedside back to bench" model, where patient's needs drive our prioritized portfolio of research. Read in detail our research strategy, and learn how we intend to achieve and measure our goals.

ARC’s research on Hereditary Transthyretin Amyloidosis (hATTR): Burden of Disease and Treatment Perspectives, was presented at the XII Paulista Congress of Neurology in Brazil. The English version of the poster is translated from Portuguese, and the data can be used by the Brazilian HTA during their evaluation of new treatments for patients with hATTR neuropathy.